What is SpineGuard?
Founded in 2009, SpineGuard is dedicated to the development and commercialization of its DSG technology, which provides surgeons with real-time, actionable data during complex skeletal procedures. By integrating sensor-based guidance into surgical instrumentation, the company effectively mitigates the risks associated with implant placement, thereby enhancing outcomes for patients and streamlining workflows for operating room staff. SpineGuard operates at the intersection of medtech and digital health, positioning itself as an essential partner for healthcare providers seeking to improve surgical accuracy and reduce complications. Its market position is defined by a commitment to clinical excellence and the continuous refinement of its proprietary guidance platform.
How much funding has SpineGuard raised?
SpineGuard has raised a total of $28M across 4 funding rounds:
Stock Offering
$10.5M
Debt
$8.4M
Other Financing Round
$8M
Share Placement
$1.1M
Stock Issuance/Offering (2013): $10.5M, investors not publicly disclosed
Debt (2016): $8.4M led by Bpifrance and IPF Partners
Other Financing Round (2023): $8M supported by Nice & Green
Share Placement (2025): $1.1M, investors not publicly disclosed
Key Investors in SpineGuard
Bpifrance
A French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong focus on innovation and international expansion.
IPF Partners
A specialized alternative financing provider focused exclusively on the healthcare sector, offering tailored debt and equity solutions for medtech and biopharma companies.
Nice & Green
A Swiss-based private investment firm that provides bespoke funding and liquidity solutions for small and medium-sized enterprises across the European market.
What's next for SpineGuard?
With the recent influx of capital, SpineGuard is well-positioned to accelerate the adoption of its DSG technology as a global standard of care. The strategic focus will likely shift toward expanding market penetration and deepening the integration of its guidance systems within existing surgical ecosystems. By leveraging this major enterprise-level funding, the company aims to scale its commercial operations and invest in further research and development to address emerging challenges in orthopedic and neurosurgical procedures. As SpineGuard navigates its next phase of growth, the emphasis remains on delivering measurable clinical benefits while maximizing value for its shareholders and the broader healthcare community.
See full SpineGuard company page
